INT306533

Context Info Confidence 0.41 First Reported 2010 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 1 Disease Relevance 0.41 Pain Relevance 0.03

Pain Term Frequency Confidence Heat Bioavailability 2 62.24 Angina 1 5.00 ischemia 2 5.00 cva 1 5.00

Disease Term Frequency Confidence Heat Hemorrhage 17 97.96 Acute Coronary Syndrome 35 95.36 Myocardial Infarction 8 71.60 Renal Insufficiency 1 47.44 Anaemia 1 5.00 Infarction 1 5.00 Thrombosis 15 5.00 Coronary Heart Disease 1 5.00 Death 7 5.00 Angina 1 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Two large randomized trials have compared bivalirudin to a combination of UFH and anti-GP IIb/IIIa inhibitors, and showed that efficacy was similar, with fewer bleeding events under bivalirudin therapy in the setting of NSTE-ACS,7 and a reduction in mortality in the setting of STEMI treated by primary angioplasty.8

Negative_regulation (inhibitors) of anti-GP IIb associated with acute coronary syndrome and hemorrhage

1) Confidence 0.41 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2856573 Disease Relevance 0.41 Pain Relevance 0.03

General Comments

This test has worked.